Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Nov 06, 2023 8:00 am EST

Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System

Nov 03, 2023 4:00 pm EDT

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 30, 2023 8:00 am EDT

IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India

Oct 25, 2023 8:00 am EDT

Independent Scientific Paper by Doctors Using IceCure's ProSense® Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients

Oct 05, 2023 8:00 am EDT

Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

Oct 02, 2023 8:00 am EDT

Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate

Sep 22, 2023 8:00 am EDT

Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023

Sep 20, 2023 7:00 am EDT

IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer

Sep 08, 2023 8:00 am EDT

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Sep 05, 2023 8:00 am EDT

IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023